von Willebrand Disease

Pediatric Clinics of North America

Volumn 55, Issue 2, 2008, Pages 377-392

  Robertson, Jeremy ^a   Lillicrap, David ^b   James, Paula D ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; DESMOPRESSIN; ESTROGEN DERIVATIVE; FIBRIN GLUE; TRANEXAMIC ACID; VASOPRESSIN; VON WILLEBRAND FACTOR;

ANAMNESIS; AUTOSOMAL INHERITANCE; BINDING AFFINITY; BLEEDING DISORDER; BLOOD COMPONENT THERAPY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENURESIS; HISTORY OF MEDICINE; HUMAN; LABORATORY TEST; MENORRHAGIA; MOLECULAR CLONING; PROTEIN SYNTHESIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

CHILD; HUMANS; VON WILLEBRAND DISEASE;

EID: 41149173233     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2008.01.008     Document Type: Review

References (66)

1. von Willebrand E.A. Hereditar pseudohemofili. Fin Lakaresallsk Handl 67 (1926) 7-112
2. Sadler J.E., Shelton-Inloes B.B., Sorace J.M., et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci U S A 82 (1985) 6394-6398
3. Ginsburg D., Handin R.I., Bonthron D.T., et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228 (1985) 1401-1403
4. Verweij C.L., Diergaarde P.J., Hart M., et al. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J 5 (1986) 1839-1847
5. Lynch D.C., Zimmerman T.S., Collins C.J., et al. Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 41 (1985) 49-56
6. Mancuso D.J., Tuley E.A., Westfield L.A., et al. Structure of the gene for human von Willebrand factor. J Biol Chem 264 33 (1989) 19514-19527
7. Titani K., Kumar S., Takio K., et al. Amino acid sequence of human von Willebrand factor. Biochemistry 25 (1986) 3171-3184
8. Hampshire D. The University of Sheffield ISTH SSC VWF database. Available at: http://www.vwf.group.shef.ac.uk/. Accessed on January 3, 2008.
9. Mancuso D.J., Tuley E.A., Westfield L.A., et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 30 (1991) 253-269
10. Wagner D.D., and Marder V.J. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 99 (1984) 2123-2130
11. Sporn L.A., Chavin S.I., Marder V.J., et al. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 76 (1985) 1102-1106
12. Ruggeri Z., and Zimmerman T. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57 (1981) 1140-1143
13. Dong J.F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100 (2002) 4033-4039
14. Savage B., Saldivar E., and Ruggeri Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84 (1996) 289-297
15. Ruggeri Z.M. Mechanisms of shear-induced platelet adhesion and aggregation. Thromb Haemost 70 (1993) 119-123
16. Koedam J.A., Meijers J.C., Sixma J.J., et al. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 82 (1988) 1236-1243
17. Rodeghiero F., Castaman G., and Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69 (1987) 454-459
18. Werner E.J., Broxson E.H., Tucker E.L., et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 123 (1993) 893-898
19. Bowman M., James P., Godwin M., et al. The prevalence of VWD in the primary care setting. Blood 106 (2007) 1780 [(ASH Annual Meeting abstracts)]
20. Sadler J.E., Mannucci P.M., Berntorp E., et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 84 (2000) 160-174
21. Dean J.A., Blanchette V.S., Carcao M.D., et al. von Willebrand disease in a pediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 84 (2000) 401-409
22. Katsanis E., Luke K.H., Hsu E., et al. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. J Pediatr 113 (1988) 73-76
23. Mannucci P.M., Pareti F.I., Holmberg L., et al. Studies on the prolonged bleeding time in von Willebrand's disease. J Lab Clin Med 88 (1976) 662-673
24. Fressinaud E., Veyradier A., Truchaud F., et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 91 (1998) 1325-1331
25. Favaloro E.J. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 32 (2006) 537-545
26. Howard M.A., and Firkin B.G. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 26 (1971) 362-369
27. Cooney K.A., Lyons S.E., and Ginsburg D. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. Proc Natl Acad Sci U S A 89 (1992) 2869-2872
28. Hoyer L.W., Rizza C.R., Tuddenham E.G.D., et al. Von Willebrand factor multimer patterns in von Willebrand's disease. Br J Haematol 55 (1983) 493-507
29. Gill J.C., Endres-Brooks J., Bauer P.J., et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 (1987) 1691-1695
30. Casonato A., Pontara E., Bertomoro A., et al. Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. Haematologica 88 (2003) 688-693
31. Stakiw J., Bowman M., Hegadorn C., et al. The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost 6 (2008) 90-96
32. Kadir R.A., and Chi C. Women and von Willebrand disease: controversies in diagnosis and management. Semin Thromb Hemost 32 (2006) 605-615
33. Andrew M., Vegh P., Johnston M., et al. Maturation of the hemostatic system during childhood. Blood 80 (1992) 1998-2005
34. Sosothikul D., Seksarn P., and Lusher J.M. Pediatric reference values for molecular markers in hemostasis. J Pediatr Hematol Oncol 29 (2007) 19-22
35. Sadler J.E., Budde U., Eikenboom J.C., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4 (2006) 2103-2114
36. Sadler J.E. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 101 (2003) 2089-2093
37. James P.D., Notley C., Hegadorn C., et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 109 (2007) 145-154
38. Goodeve A., Eikenboom J., Castaman G., et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand disease (MCMDM-1VWD). Blood 109 (2007) 112-121
39. O'Brien L.A., James P.D., Othman M., et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 102 (2003) 549-557
40. Lyons S.E., Bruck M.E., Bowie E.J.W., et al. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 267 (1992) 4424-4430
41. Ruggeri Z.M., Pareti F.I., Mannucci P.M., et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 302 (1980) 1047-1051
42. Miller J.L., and Castella A. Platelet-type von Willebrand's disease: characterization of a new bleeding disorder. Blood 60 (1982) 790-794
43. Brychaert M.C., Pietu G., Ruan C., et al. Abnormality of glycoprotein Ib in two cases of "pseudo" von Willebrand's disease. J Lab Clin Med 106 (1985) 393-400
44. Mancuso D.J., Kroner P.A., Christopherson P.A., et al. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets. Blood 88 (1996) 2559-2568
45. Mazurier C. von Willebrand disease masquerading as haemophilia A. Thromb Haemost 67 (1992) 391-396
46. Nesbitt I.M., Goodeve A.C., Guilliatt A.M., et al. Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques. Thromb Haemost 75 (1996) 959-964
47. Castaman G., Rodeghiero F., Tosetto A., et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 4 (2006) 2164-2169
48. Baronciani L., Cozzi G., Canciani M.T., et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 30 (2003) 264-270
49. Shelton-Inloes B., Chehab F., Mannucci P., et al. Gene deletions correlate with the development of alloantibodies in von Willebrand's disease. J Clin Invest 79 (1987) 1459-1465
50. Ngo K., Glotz Trifard V., Koziol J., et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci U S A 85 (1988) 2753-2757
51. Mannucci P.M. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72 (1988) 1449-1455
52. Rodeghiero F., Castaman G., Di Bona E., et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 74 (1989) 1997-2000
53. Rose E.H., and Aledort L.M. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 114 (1991) 563-568
54. Humphries J.E., and Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 44 (1993) 12-15
55. Weinstein R.E., Bona R.D., Altman A.J., et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 32 (1989) 258-261
56. Mannucci P.M., Bettega D., and Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 82 (1992) 87-93
57. Federici A.B., Mazurier C., Berntorp E., et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 103 (2004) 2032-2038
58. Haberichter S.L., Balistreri M., Christopherson P., et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 108 (2006) 3344-3351
59. Fowler W.E., Berkowitz L.R., and Roberts H.R. DDAVP for type IIB von Willebrand disease. Blood 74 (1989) 1859-1860
60. Casonato A., Sartori M.T., De Marco L., et al. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost 64 (1990) 117-120
61. Mazurier C., Gaucher C., Jorieux S., et al. Biological effect of desmopressin in eight patients with type 2N (Normandy) von Willebrand disease. Br J Haematol 88 (1994) 849-854
62. Rodeghiero F., Castaman G., Meyer D., et al. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 62 (1992) 193-199
63. Mannucci P.M., Chediak J., Hanna W., et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99 (2002) 450-456
64. Lillicrap D., Poon M.C., Walker I., et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 87 (2002) 224-230
65. Mannucci P.M. Venous thromboembolism in von Willebrand disease. Thromb Haemost 88 (2002) 378-379
66. Castillo R., Monteagudo J., Escolar G., et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood 77 (1991) 1901-1905